Alumis (ALMS) Research & Development (2023 - 2026)
Alumis' (ALMS) quarterly Research & Development came in at $85.3 million in Q2 2026, down 21.53% year-over-year from $108.8 million in Q2 2025, and up 3.08% quarter-over-quarter from $82.8 million in Q4 2025.
Analysis
Alumis (ALMS) Research & Development (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Research & Development for 4 consecutive years, with $85.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Research & Development fell 21.53% year-over-year to $85.3 million in Q2 2026; TTM through Jun 2026 was $374.7 million, a 1.5% decrease from a year earlier, with the FY2025 full-year figure at $386.0 million, up 45.36% from the prior year.
- Research & Development was $85.3 million for Q2 2026 at Alumis, up from $82.8 million in the prior quarter.
- Over five years, Research & Development peaked at $108.8 million in Q2 2025 and troughed at $32.8 million in Q2 2023.
- A 4-year average of $70.2 million and a median of $84.1 million in 2025 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 152.0% in 2024 and retreated 21.53% in 2026, its largest moves.
- Over 4 years, Research & Development stood at $34.6 million in 2023, then surged by 152.0% to $87.2 million in 2024, then retreated by 5.07% to $82.8 million in 2025, then increased by 3.08% to $85.3 million in 2026.
- The last three Research & Development figures came in at $85.3 million (Q2 2026), $82.8 million (Q4 2025), and $97.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Alumis | 1.27 Bn | 765.76 Mn | - | 85.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 85.34 Mn |
| Dec 31, 2025 | 82.79 Mn |
| Sep 30, 2025 | 97.84 Mn |
| Jun 30, 2025 | 108.76 Mn |
| Mar 31, 2025 | 96.62 Mn |
| Dec 31, 2024 | 87.20 Mn |
| Sep 30, 2024 | 87.82 Mn |
| Jun 30, 2024 | 48.57 Mn |
| Mar 31, 2024 | 41.96 Mn |
| Dec 31, 2023 | 34.61 Mn |
| Sep 30, 2023 | 37.79 Mn |
| Jun 30, 2023 | 32.85 Mn |